{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T01:55:08Z","timestamp":1777859708837,"version":"3.51.4"},"reference-count":38,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2020,7,31]],"date-time":"2020-07-31T00:00:00Z","timestamp":1596153600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacy Practice"],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:p>With the emergence of a novel severe acute respiratory syndrome coronavirus, investigators worldwide are scrambling to identify appropriate treatment modalities, develop accurate testing, and produce a vaccine. To date, effective treatment remains elusive. Chloroquine phosphate and hydroxychloroquine sulfate (HCQ), well-known antimalarial drugs effective in the treatment of systemic lupus erythematosus, rheumatoid arthritis, porphyria cutanea tarda, and chronic Q fever, are currently under investigation. The United States Food and Drug Administration recently issued an Emergency Use Authorization for CQ and HCQ use in the treatment of coronavirus disease 2019 (COVID-19). With spikes in HCQ use and demand, ethical considerations encompassing appropriate use, patient autonomy, nonmaleficence, and distributive justice abound. As drug experts, pharmacists are uniquely positioned to advocate for patients with chronic conditions necessitating HCQ use, assist in the appropriate prescribing of HCQ for COVID-19, and ensure patients and health care professionals are continually educated during this public health crisis. This review highlights the worldwide pandemic, describes appropriate HCQ use for chronic conditions, highlights available alternatives, and deliberates evolving ethical questions. With assistance from colleagues, state boards of pharmacy, and national organizations, pharmacists ensure the just distribution of valuable pharmaceuticals to patients having COVID-19 while supporting the needs of patients requiring HCQ for chronic conditions.<\/jats:p>","DOI":"10.1177\/0897190020942658","type":"journal-article","created":{"date-parts":[[2020,7,31]],"date-time":"2020-07-31T07:54:29Z","timestamp":1596182069000},"page":"120-125","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["Hydroxychloroquine Alternatives for Chronic Disease: Response to a Growing Shortage Amid the Global COVID-19 Pandemic"],"prefix":"10.1177","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6382-2210","authenticated-orcid":false,"given":"Sameeha S.","family":"Husayn","sequence":"first","affiliation":[{"name":"College of Osteopathic Medicine, Rocky Vista University, Parker, CO, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy D.","family":"Brown","sequence":"additional","affiliation":[{"name":"College of Osteopathic Medicine, Rocky Vista University, Parker, CO, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3646-7732","authenticated-orcid":false,"given":"Colby L.","family":"Presley","sequence":"additional","affiliation":[{"name":"College of Osteopathic Medicine, Rocky Vista University, Parker, CO, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelsey","family":"Boghean","sequence":"additional","affiliation":[{"name":"College of Osteopathic Medicine, Rocky Vista University, Parker, CO, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7467-8162","authenticated-orcid":false,"given":"Jacquelyn D.","family":"Waller","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Rocky Vista University, Parker, CO, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2020,7,31]]},"reference":[{"key":"bibr1-0897190020942658","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001191"},{"key":"bibr2-0897190020942658","unstructured":"Hinton DM. Request for emergency use authorization for use of chloroquine phosphate or hydroxychloroquine sulfate supplied from the Strategic National Stockpile for treatment of 2019 coronavirus disease. 2020. Accessed March 31, 2020. https:\/\/www.fda.gov\/media\/136534\/download"},{"key":"bibr3-0897190020942658","unstructured":"Public Health Emergency [Internet]. Strategic National Stockpile. 2020. Accessed April 3, 2020. https:\/\/www.phe.gov\/about\/sns\/Pages\/default.aspx"},{"key":"bibr4-0897190020942658","doi-asserted-by":"publisher","DOI":"10.1101\/2020.04.16.20065920"},{"key":"bibr5-0897190020942658","unstructured":"Boulware DR, Pullen MF, Bangdiwala AS, et al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. N Engl J Med. 2020. Accessed June 8, 2020. Preprint https:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMoa2016638?articleTools=true"},{"key":"bibr6-0897190020942658","unstructured":"Agency for Healthcare Research and Quality [Internet]. Number of people with purchase in thousands by prescribed drug, United States, 1996-2017. Medical Expenditure Panel Survey. 2020. Accessed April 4, 2020. https:\/\/www.meps.ahrq.gov\/mepstrends\/hc_pmed\/#plot-tab"},{"key":"bibr7-0897190020942658","unstructured":"Food and Drug Administration [Internet]. FDA Drug Shortages. 2020. Accessed April 7, 2020. https:\/\/www.accessdata.fda.gov\/scripts\/drugshortages\/default.cfm"},{"key":"bibr8-0897190020942658","unstructured":"Food and Drug Administration [Internet]. FDA Drug Shortages. 2020. Accessed June 8, 2020. https:\/\/www.accessdata.fda.gov\/scripts\/drugshortages\/default.cfm"},{"key":"bibr9-0897190020942658","unstructured":"Plaquenil\u00ae (Hydroxychloroquine Sulfate) [Package Insert]. Concordia Pharmaceuticals. 2017. Accessed April 1, 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/009768s037s045s047lbl.pdf"},{"key":"bibr10-0897190020942658","unstructured":"Hydroxychloroquine: Drug information. In: UpToDate [Internet]. 2020. Accessed April 17, 2020. http:\/\/www.uptodate.com"},{"key":"bibr11-0897190020942658","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199101173240303"},{"key":"bibr12-0897190020942658","unstructured":"Centers for Disease Control and Prevention. Treatment of malaria: guidelines for clinicians (United States). 2020. Accessed April 7, 2020. https:\/\/www.cdc.gov\/malaria\/diagnosis_treatment\/clinicians1.html#"},{"key":"bibr13-0897190020942658","unstructured":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. National Institute of Diabetes and Digestive and Kidney Diseases; 2012- Antimalarial Agents. 2017. Accessed April 7, 2020. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548220\/"},{"key":"bibr14-0897190020942658","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2014.1720"},{"key":"bibr15-0897190020942658","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.101766"},{"issue":"10","key":"bibr16-0897190020942658","first-page":"4485","volume":"71","author":"Naveau T","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"bibr17-0897190020942658","doi-asserted-by":"publisher","DOI":"10.1177\/0961203317749046"},{"key":"bibr18-0897190020942658","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2011.150"},{"key":"bibr19-0897190020942658","unstructured":"Lupus Foundation of America [Internet]. Hydroxychloroquine: benefits, side effects, and dosing. 2020. Accessed April 4, 2020. https:\/\/www.lupus.org\/resources\/drug-spotlight-on-hydroxychloroquine"},{"key":"bibr20-0897190020942658","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv018"},{"key":"bibr21-0897190020942658","unstructured":"Benjamin O, Bansal P, Goyal A, et al. Disease Modifying Anti-Rheumatic Drugs (DMARD). In: StatPearls. StatPearls Publishing; 2020. Accessed April 7, 2020. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK507863\/"},{"key":"bibr22-0897190020942658","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-020-0372-x"},{"key":"bibr23-0897190020942658","unstructured":"Singh JA, Saag KG, Bridges SLJr, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2016;68(1):1\u201325. Accessed April 16, 2020. https:\/\/pubmed.ncbi.nlm.nih.gov\/26545825\/"},{"key":"bibr24-0897190020942658","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2012.08.038"},{"key":"bibr25-0897190020942658","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2019.01.004"},{"key":"bibr26-0897190020942658","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1983.tb01062.x"},{"key":"bibr27-0897190020942658","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00185-12"},{"key":"bibr28-0897190020942658","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02365-05"},{"key":"bibr29-0897190020942658","unstructured":"World Health Organization. Guidelines for the Treatment of Malaria, 3rd ed. World Health Organization; 2015. Accessed April 17, 2020. http:\/\/www.who.int\/malaria\/publications\/atoz\/9789241549127\/en\/"},{"key":"bibr30-0897190020942658","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215089"},{"key":"bibr31-0897190020942658","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix886"},{"key":"bibr32-0897190020942658","unstructured":"National Institutes of Health [Internet]. COVID-19 | Hydroxychloroquine. 2020. Accessed April 16, 2020. ClinicalTrials.gov"},{"key":"bibr33-0897190020942658","unstructured":"COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. 2020. Accessed June 12, 2020. https:\/\/www.covid19treatmentguidelines.nih.gov\/"},{"key":"bibr34-0897190020942658","unstructured":"Hinton DM. Request for emergency use authorization for use of remdesivir for the treatment of hospitalized 2019 coronavirus disease. 2020. Accessed June 10, 2020. https:\/\/www.fda.gov\/media\/137564\/download"},{"key":"bibr35-0897190020942658","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31022-9"},{"key":"bibr36-0897190020942658","unstructured":"Lupus Foundation of America. Hydroxychloroquine (Plaquenil) and coronavirus (COVID-19) questions and answers. 2020. Accessed April 6, 2020. https:\/\/www.lupus.org\/resources\/hydroxychloroquine-plaquenil-coronavirus-covid19-questions-answers"},{"key":"bibr37-0897190020942658","unstructured":"American Medical Association. Joint statement on ordering, prescribing or dispensing COVID-19 medications. 2020. Accessed June 10, 2020. https:\/\/www.ama-assn.org\/delivering-care\/public-health\/joint-statement-ordering-prescribing-or-dispensing-covid-19"},{"key":"bibr38-0897190020942658","unstructured":"American Medical Association. Boards of pharmacy and other actions relating to COVID-19 prescribing. 2020. Accessed June 10, 2020. https:\/\/www.ama-assn.org\/system\/files\/2020-04\/board-of-pharmacy-covid-19-prescribing.pdf"}],"container-title":["Journal of Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0897190020942658","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0897190020942658","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0897190020942658","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:36:08Z","timestamp":1777509368000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0897190020942658"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,31]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["10.1177\/0897190020942658"],"URL":"https:\/\/doi.org\/10.1177\/0897190020942658","relation":{},"ISSN":["0897-1900","1531-1937"],"issn-type":[{"value":"0897-1900","type":"print"},{"value":"1531-1937","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,31]]}}}